Advanced search
Publication Cover
Leukemia & Lymphoma Volume 57, 2016 - Issue 10
Submit an article Journal homepage
371
Views
2
CrossRef citations to date
0
Altmetric
Letters to the Editor

Investigating the synergistic mechanism between ibrutinib and daunorubicin in acute myeloid leukemia cells

Lianne E. RotinPrincess Margaret Cancer Centre, Ontario Cancer Institute, University Health Network, Toronto, ON, Canada; ;Institute of Medical Science, University of Toronto, Toronto, ON, Canada;
,
Marcela GrondaPrincess Margaret Cancer Centre, Ontario Cancer Institute, University Health Network, Toronto, ON, Canada;
,
Rose HurrenPrincess Margaret Cancer Centre, Ontario Cancer Institute, University Health Network, Toronto, ON, Canada;
,
XiaoMing WangPrincess Margaret Cancer Centre, Ontario Cancer Institute, University Health Network, Toronto, ON, Canada;
,
Mark D. MindenPrincess Margaret Cancer Centre, Ontario Cancer Institute, University Health Network, Toronto, ON, Canada;
,
Malik SlassiFluorinov Pharma Inc., Toronto, ON, Canada
&
Aaron D. SchimmerPrincess Margaret Cancer Centre, Ontario Cancer Institute, University Health Network, Toronto, ON, Canada; ;Institute of Medical Science, University of Toronto, Toronto, ON, Canada; Correspondence[email protected]
 show all
Pages 2432-2436 | Received 17 Aug 2015, Accepted 31 Dec 2015, Published online: 17 Feb 2016

References

  • Rushworth SA, Murray MY, Zaitseva L, et al. Identification of Bruton’s tyrosine kinase as a therapeutic target in acute myeloid leukemia. Blood. 2014;123:1229–1238.
  • Oellerich T, Mohr S, Corso J, et al. FLT3-ITD and TLR9 use Bruton tyrosine kinase to activate distinct transcriptional programs mediating AML cell survival and proliferation. Blood. 2015;125:1936–1947.
  • Zaitseva L, Murray MY, Shafat MS, et al. Ibrutinib inhibits SDF1/CXCR4 mediated migration in AML. Oncotarget. 2014;5:9930–9938.
  • Quentmeier H, Reinhardt J, Zaborski M, et al. FLT3 mutations in acute myeloid leukemia cell lines. Leukemia. 2003;17:120–124.
  • Borisy AA, Elliott PJ, Hurst NW, et al. Systematic discovery of multicomponent therapeutics. Proc Natl Acad Sci USA. 2003;100:7977–7982.
  • Mathews Griner LA, Guha R, Shinn P, et al. High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci USA. 2014;111:2349–2354.
  • Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA. 2010;107:13075–13080.
  • Manjunath N, Wu H, Subramanya S, et al. Lentiviral delivery of short hairpin RNAs. Adv Drug Deliv Rev. 2009;61:732–745.
  • Lainey E, Sébert M, Thépot S, et al. Erlotinib antagonizes ABC transporters in acute myeloid leukemia. Cell Cycle 2012;11:4079–4092.
  • Zhang H, Patel A, Ma S, et al. In vitro, in vivo and ex vivo characterization of ibrutinib: a potent inhibitor of the efflux function of the transporter MRP1. Br J Pharmacol. 2014;171:5845–5857.
  • Rotin LE, Gronda M, MacLean N, et al. Ibrutinib sensitizes AML cells to ROS inducers via a BTK-independent mechanism [abstract]. Blood. 2014;124:2226.
  • Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol. 1999;57:727–741.
  • Dasmahapatra G, Patel H, Dent P, et al. The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib. Br J Haematol. 2013;161:43–56.
  • Pédeboscq S, Rey C, Petit M, et al. Non-antioxidant properties of α-tocopherol reduce the anticancer activity of several protein kinase inhibitors in vitro. PLoS One. 2012;7:e36811.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.